

Remicade (Infliximab) Patient Referral and Prescription Sheet

| Patient Information | | | | | | | | | | |
|---|---|---|------------|-----------|------------------------------|-----------|--------------------|---------------|--|--|
| Patient Name: | | | | | | Date: | | | | |
| DOB: | | | | | | Height: | | 🗅 inches 🕒 cm | | |
| Allergies: | | | | | | Weight: | | 🗆 lbs 🔲 kg | | |
| Primary Diagnosis | | | | | | | | | | |
| Diagnosis | Diagnosis | Diagnosis | | | | | | | | |
| Crohn's Disease of | Crohn's Di | □ Crohn's Disease of large intestine without complications | | | | | | | | |
| Crohn's Disease, ur | Ulcerative | Ulcerative Chronic pancolitis without complications K51.00 | | | | | | | | |
| Plaque Psoriasis | Psoriatic P | □ Psoriatic Psoriasis L40.52 | | | | | | | | |
| Rheumatoid arthrit | M06.9 | Ankylosing Spondylitis M45. | | | | | M45.9 | | | |
| Ulcerative Colitis, u | □ Other | | | | | | | | | |
| Medication Order | | | | | | | | | | |
| 🗆 Remicade | Renflexis | Avsola | Infliximab | Inflectra | | Zymfentra | Refills x one year | | | |
| Dosing: from date of Initiation: Administermg/kg IV over at least two hours at weeks 0, 2 and 6 per protocol signature unless Maintenance: Administermg/kg IV overminutes everyweeks indicated below Round to the nearest 100mg vial size OR exact dose of:mg weeks 120mg SC every 2 weeks minutes everyweeks Other | | | | | | | | ost- | | |
| Anaphylaxis Protocol: Epinephrine Auto-Injector dual pack: Adult: 0.3mg Children: 0.15 mg | | | | | | | | | | |
| Administer epinephrine IM in the event of anaphylaxis. May repeat x 1 as needed, Call 911. Refill x 1yr | | | | | | | | | | |
| Therapy Specific Documentation | | | | | Other Required Documentation | | | | | |
| Please include the fol CMP CBC LFTs CRP Infliximab Trough L Other | authorizat H & P OR Medicatio with dates Hepatitis I Hepatitis I | Patient Demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise. H & P OR progress note(s) Medication List- Please list past and present DMARDS/biologics below with dates of discontinue, if applicable Hepatitis B Surface Antigen Hepatitis B Core Antibody Total (not Core IgM) QuantiFERON-TB Gold | | | | | | | | |
| Provider Information | | | | | | | | | | |
| Provider Name: | | | | | Provider Phone: | | | | | |
| Provider NPI: | | | | | Provider Fax: | | | | | |
| Provider Address: | | | | | | | | | | |
| | | | | | | | | | | |

I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription and any future refills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Prescriber Signature: _

Date: ____

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other document. Thank you.